Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome
| Autor: | Abel López-Bermejo, José M. Gallego-Escuredo, Francesc Villarroya, Lourdes Ibáñez, Francis de Zegher, Marta Díaz |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Síndrome dels ovaris poliquístics Article Subject Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Ovary diseases lcsh:Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences chemistry.chemical_compound Noies adolescents 0302 clinical medicine Endocrinology Endocrinologia Internal medicine medicine Pioglitazone/Metformin Malalties de l'ovari lcsh:RC648-665 Teenage girls Endocrine and Autonomic Systems business.industry Insulin medicine.disease Polycystic ovary Metformin chemistry Spironolactone Metabolic syndrome business Body mass index Pioglitazone Research Article medicine.drug Glicoproteïnes |
| Zdroj: | Repositorio Abierto de la UdL Universitad de Lleida Recercat: Dipósit de la Recerca de Catalunya Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) International Journal of Endocrinology, Vol 2018 (2018) Recercat. Dipósit de la Recerca de Catalunya instname Dipòsit Digital de la UB Universidad de Barcelona International Journal of Endocrinology |
| Popis: | Background. Fetuin-A is a glycoprotein produced in the liver and related to metabolic syndrome; fetuin-A secretion is divergently regulated in different pathological conditions. In girls with polycystic ovary syndrome (PCOS), insulin sensitization results in a more favorable endocrine-metabolic outcome than oral contraception; we assessed whether those differences are underscored by changes in circulating fetuin-A. Methods. Fetuin-A concentration endocrine-metabolic markers and hepatovisceral fat were measured longitudinally in 35 PCOS girls [age, 16 yr; body mass index (BMI), 23 kg/m2] randomized to receive either oral contraception [ethinylestradiol-levonorgestrel (n=18)] or a low-dose combination of spironolactone, pioglitazone, and metformin (SPIOMET, n=17) over 12 months. Healthy adolescent girls (age- and BMI-matched) were used as controls (n=25). Results. Pretreatment fetuin-A serum levels in PCOS girls were lower than those in controls. After 12 months on treatment, fetuin-A raised to control levels only in the SPIOMET subgroup (P=0.009, versus oral contraception); this increase was paralleled by a healthier metabolic profile with less hepatic fat (by MRI); baseline serum fetuin-A as well as the changes over 12 months was inversely related to hepatic adiposity. Conclusions. A low-dose combination of insulin sensitizers and an antiandrogen—but not oral contraception—normalizes fetuin-A levels in adolescent girls with PCOS. This trial is registered with ISRCTN29234515. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|